HC devotees of Noxopharm know more about NOX than stockbrokers, in my opinion, and yet we have missed a major story. Nyrada today announced stunning pre-clinical results for its oral cholesterol drug, in a mouse model that is known to predict response in humans, suggesting that NYX-PCSK9i is potentially better that the best-selling drug of all time. Noxopharm owns about 30% of Nyrada.
But we did not miss everything. For instance, we knew about the Notice of Allowance in Europe that was announced today, but we also know that a couple of patent grants are looking particularly good in the USA; and we also know that a Notice of Allowance was issued in the USA for Nyrada's cholesterol drug on 6 April 2021. The stagnant share price of Nyrada suggests that the Market has not made this connection.
Nyrada is a hidden gem, in my view, as is Pharmorage.
NOX Price at posting:
64.0¢ Sentiment: Buy Disclosure: Held
